Trial reportProceedings of the National Academy of Sciences of the United States of America2012
Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.NPJ vaccines · 2025Article
- Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.Theranostics · 2025Review
- Review
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.Science (New York, N.Y.) · 2023Article
- Human leukocyte immunoglobulin-like receptors in health and disease.Frontiers in immunology · 2023Review
- Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of theMolecular therapy oncolytics · 2022Article
- New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells.Viruses · 2022Review
- Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy.JCI insight · 2022Review
- Identification of Genes Encoding Antimicrobial Proteins in Langerhans Cells.Frontiers in immunology · 2021Article
- LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.JCI insight · 2020Article
- Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.The Journal of clinical investigation · 2018Article
- Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs.Cellular and molecular life sciences : CMLS · 2018Article
- A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease.JCI insight · 2017Article
- LILRB receptor-mediated regulation of myeloid cell maturation and function.Cancer immunology, immunotherapy : CII · 2017Review
- Two Distinct Myeloid Subsets at the Term Human Fetal-Maternal Interface.Frontiers in immunology · 2017Article
- Molecular and Cellular Characterization of Human CD8 T Suppressor Cells.Frontiers in immunology · 2016Review
- Leukocyte Ig-Like Receptors - A Model for MHC Class I Disease Associations.Frontiers in immunology · 2016Review
- Article
- Modular expression analysis reveals functional conservation between human Langerhans cells and mouse cross-priming dendritic cells.The Journal of experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
Abstract
Human Langerhans cells (LCs) are highly efficient at priming cytolytic CD8(+) T cells compared with dermal CD14(+) dendritic cells (DCs). Here we show that dermal CD14(+) DCs instead prime a fraction of naïve CD8(+) T cells into cells sharing the properties of type 2 cytokine-secreting CD8(+) T cells (TC2). Differential expression of the CD8-antagonist receptors on dermal CD14(+) DCs, the Ig-like transcript (ILT) inhibitory receptors, explains the difference between the two types of DCs. Inhibition of CD8 function on LCs inhibited cytotoxic T lymphocytes (CTLs) and enhanced TC2 generation. In addition, blocking ILT2 or ILT4 on dermal CD14(+) DCs enhanced the generation of CTLs and inhibited TC2 cytokine production. Lastly, addition of soluble ILT2 and ILT4 receptors inhibited CTL priming by LCs. Thus, ILT receptor expression explains the polarization of CD8(+) T-cell responses by LCs vs. dermal CD14(+) DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.